| Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. | |
| | |
MedLine Citation:
|
PMID: 16133893 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Multiple factors can affect the anticoagulation effect of warfarin. The objective of this study was to determine the relationship between different clinical factors and outcomes of warfarin therapy in Hong Kong Chinese patients. METHODS: The study was conducted at the anticoagulation clinic of the Prince of Wales Hospital from 1 April to 31 December 2003. Clinical data collected included demographics, indications of warfarin, dietary vitamin K consumption, and drug-drug interactions. Blood samples were obtained for the genetic polymorphism analysis of CYP 2 C 9. Linear and multiple regression analysis were used for statistical analysis to determine the correlation between variables and the importance of various factors as the determinants of warfarin dosage requirement. RESULTS: A total of 63 patients were recruited. The mean warfarin dosage was 3.30+/-2.23 mg/day. The warfarin dosage ranged from 0.75 to 12 mg/day. The mean age was 59+/-14 years old. Age, dietary vitamin K consumption, chronic heart failure, atrial fibrillation, hypertension, smoking and drinking status were found to be factors statistically significant affecting warfarin dosage. We detected no single nucleotide polymorphism in CYP 2 C 9 exon 4. CONCLUSION: Age, dietary vitamin K consumption, warfarin indication for atrial fibrillation, co-morbid with CHF, smoking and drinking status were found to be the factors that affected the warfarin requirement in Hong Kong Chinese patients. However, the genetic polymorphism in exon 4 of CYP 2 C 9 may not be associated with the warfarin sensitivity in this patient population. |
| | |
Authors:
|
Vivian W Y Lee; Joyce H S You; Kenneth K C Lee; T S Chau; Mary M Y Waye; Gregory Cheng |
Related Documents
:
|
789043 - Antithrombotic drugs: part i. 16807653 - Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ische... 19727333 - Beyond post-marketing research and medwatch: long-term studies of drug risks. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 20 ISSN: 0929-5305 ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2005-08-31 Completed Date: 2005-11-15 Revised Date: 2010-03-23 |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 33-8 Citation Subset: IM |
Affiliation:
|
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong. vivianlee@cuhk.edu.hk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anticoagulants / therapeutic use Aryl Hydrocarbon Hydroxylases / genetics Asian Continental Ancestry Group Cardiovascular Diseases / classification, drug therapy*, genetics Dose-Response Relationship, Drug Exons Female Hong Kong Humans International Normalized Ratio Male Middle Aged Polymorphism, Genetic Polymorphism, Single Nucleotide Regression Analysis Retrospective Studies Warfarin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 81-81-2/Warfarin; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C9 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An investigation of the physical forces leading to thrombosis disruption by cavitation.
Next Document: Left atrial free-floating ball thrombus in a case of hyperthrophic cardiomyopathy.